CSCO 2024: Dr. Zhiming Li Champions New Frontiers in Lymphoma Management

CSCO 2024: Dr. Zhiming Li Champions New Frontiers in Lymphoma Management

2024.10.25
From September 25 to September 29, the 27th National Clinical Oncology Conference and CSCO Annual Meeting, organized by the Chinese Society of Clinical Oncology (CSCO) and the Beijing Xisike Clinical Oncology Research Foundation, was successfully held in Xiamen. During the conference, Hematology Frontier invited Dr. Zhiming Li from Sun Yat-sen University Cancer Center to share his strategies for treating diffuse large B-cell lymphoma (DLBCL).
CAR-T vs. Bispecific Antibodies: Dr. Junmin Song’s Groundbreaking Myeloma Study at ESMO 2024

CAR-T vs. Bispecific Antibodies: Dr. Junmin Song’s Groundbreaking Myeloma Study at ESMO 2024

2024.10.25
The 2024 Annual Meeting of the European Society for Medical Oncology (ESMO) was recently held in Barcelona, Spain. As one of the premier global oncology conferences, it brought together experts and scholars from around the world to share cutting-edge research and chart future directions. During the conference, Dr. Junmin Song from the Jacobi Medical Center, Albert Einstein College of Medicine, presented the first real-world study comparing BCMA CAR-T therapy with bispecific antibodies in the treatment of multiple myeloma (802MO). This presentation garnered significant attention from attendees. Hematology Frontier invited Dr. Song to provide an in-depth interpretation of the study and to discuss the future prospects of these two innovative therapies in multiple myeloma treatment.
Dr. Conconi at ESMO 2024: Charting the Course for Hematologic Malignancies Treatment

Dr. Conconi at ESMO 2024: Charting the Course for Hematologic Malignancies Treatment

2024.10.25
The 2024 Annual Meeting of the European Society for Medical Oncology (ESMO) was recently held in Barcelona, Spain. As one of the top international conferences in the field of oncology, it gathered experts and scholars from around the world to share the latest research findings and explore future development directions. During this conference, several landmark studies in the field of hematologic malignancies were presented, providing valuable insights and references for current clinical practice and future research. Hematology Frontier invited Dr. Annarita Conconi from the University of Eastern Piedmont in Italy, one of the Chairs of the Mini Oral Session on Hematologic Malignancies, to comment on these landmark studies and to look ahead at the future trends in hematologic oncology.
Groundbreaking Honors at ILCA 2024: Celebrating Liver Cancer Research Milestones

Groundbreaking Honors at ILCA 2024: Celebrating Liver Cancer Research Milestones

2024.10.24
The 2024 International Liver Cancer Association (ILCA) Conference recently held its highly anticipated awards ceremony in Rio de Janeiro, Brazil. This event attracted attention from liver cancer researchers worldwide, recognizing those who made significant contributions to the field over the past year. The ceremony aimed to further promote global collaboration and innovation in liver cancer research.
IMS 2024丨Dr. Juan Li’s Team: Tandem ASCT as a Potentially Effective Strategy for High-Risk MM Patients with Dual Hits of 1q21 Amplification and t(4;14)

IMS 2024丨Dr. Juan Li’s Team: Tandem ASCT as a Potentially Effective Strategy for High-Risk MM Patients with Dual Hits of 1q21 Amplification and t(4;14)

2024.10.24
From September 25 to 28, 2024, the 21st International Myeloma Society (IMS) Annual Meeting was held in Rio de Janeiro, Brazil. At this prestigious conference, the research led by Dr. Juan Li from The First Affiliated Hospital of Sun Yat-sen University in China was selected for poster presentation. The study suggests that for high-risk multiple myeloma (MM) patients with dual hits of 1q21 amplification and t(4;14), tandem autologous stem cell transplantation (Tandem ASCT) might be an effective treatment strategy. Hematology Frontier invited Professor Li to share the findings of this study and its clinical significance.
Advancing the Field: Dr. Pei Dong Discusses Groundbreaking Neoadjuvant Therapies for Renal Cancer at CSCO 2024

Advancing the Field: Dr. Pei Dong Discusses Groundbreaking Neoadjuvant Therapies for Renal Cancer at CSCO 2024

2024.10.24
Surgery is a fundamental treatment for renal cancer, particularly for patients with stage I and II cancers, where surgery can cure the majority of cases and ensure long-term survival. At the 2024 CSCO Annual Meeting, Urology Frontier invited Dr. Pei Dong from Sun Yat-sen University Cancer Center to discuss this year’s key updates in the CSCO guidelines for surgical treatment of renal cancer, comparisons between single-port and traditional laparoscopic nephrectomy, and the role of neoadjuvant therapy in enhancing surgical outcomes.